Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Vyriad, Inc. Appoints Scott Beck as Chief Operating Officer
Vyriad, Inc., a biotechnology company developing oncolytic virus therapies to treat a wide range of […]
The Scottish Medicines Consortium (SMC) Recommends Use of Hansa Biopharma’s Idefirix® (Imlifidase) as Desensitization Treatment for Highly Sensitized Kidney Transplant Patients
Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, […]
SeekIn Receives CE Mark Approval for OncoSeek® Multi-Cancer Detection Test
SeekIn Inc, a leader in blood-based cancer early detection and monitoring technology, today announced CE […]
Compugen Announces Appointment of Alberto Sessa as Chief Financial Officer
Compugen Ltd. ( Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced […]
Zejula (Niraparib) Shows Durable and Sustained Long-term Progression-free Survival Benefit in the Prima Study of First-line Platinum-responsive Advanced Ovarian Cancer
GSK plc (LSE/NYSE: GSK) today announced long-term data from the phase III PRIMA (ENGOT-OV26/GOG-3012) study […]
Novel Regeneron Bispecific Antibodies Show Encouraging Anti-Tumor Activity in Two Advanced Solid Tumors
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive early data for two novel and investigational bispecific […]
Privo Technologies, Inc. Awarded $2M Direct-to-Phase II Contract from the National Cancer Institute for PRV311 Treatment of Cervical Cancer
Privo Technologies, Inc. (“Privo”, “the Company”) announced today that it has been awarded a $2M Direct-to-Phase II SBIR […]
NeoImmuneTech's NT-I7 Creates a More Immunogenic Tumor Microenvironment when Associated with Pembrolizumab
NeoImmuneTech, Inc. (NIT), a T cell-focused therapeutics company, presented data that suggests that NT-I7 plus […]
Novarad Secures a Strategic Regional Network Alliance for Its Augmented Reality Surgical Navigation Product, Which Has Been Providing Unique Solutions and Cutting-edge Technologies to Neurosurgical and Spine Markets for More Than 30 Years
Novarad Corporation announces a strategic alliance with a network of well-established specialty Neurosurgical and Spine […]
Cue Health Appoints David Tsay, MD, PhD, as Chief Medical Officer
Cue Health Inc. (“Cue”) ( Nasdaq: HLTH), a healthcare technology company, today announced that it has appointed David […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more